Search

Displaying results 7211 - 7220 of 7687 in total
  1. Drug

    Alicaforsen

    go.drugbank.com/drugs/DB06224
    Investigational

  2. Drug

    FK352B

    go.drugbank.com/drugs/DB06484
    Experimental

    FK352B is a adenosine A1 antagonist that is developed for the treatment of dialysis-induced hypotension.

  3. Drug

    Tin protoporphyrin IX

    go.drugbank.com/drugs/DB16449
    Investigational

  4. Drug

    Polyinosinic-polycytidylic acid

    go.drugbank.com/drugs/DB16467
    Investigational

  5. Drug

    Vitex agnus-castus fruit extract

    go.drugbank.com/drugs/DB13193
    Investigational

    main mechanism of action of vitex agnus-castus fruit extract has not been fully elucidated, however it is suggested to modulate the stress-induced prolactin secretion via dopaminergic actions, and μ (mu

  6. Drug

    Horse chestnut

    go.drugbank.com/drugs/DB13195
    Investigational

    Unprocessed horse chestnut seeds contain a toxin called esculin (also spelled aesculin) that increases the risk of bleeding due to anticoagulant actions.

  7. Drug

    SR-123781A

    go.drugbank.com/drugs/DB05361
    Investigational

    SR-123781A is a synthetic hexadecasaccharide Factor IIa and Xa antagonist. It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).

  8. Drug

    Isatoribine

    go.drugbank.com/drugs/DB04860
    Experimental

    Isatoribine is a selective agonist of TLR7.

  9. Drug

    Zunsemetinib

    go.drugbank.com/drugs/DB16502
    Investigational

    ATI-450 was under investigation in clinical trials (NCT05279417 and NCT05216224) for treating patients with rheumatoid arthritis and hidradenitis suppurativa, respectively. Additionally, ATI-450 was studied in a terminated trial (NCT0551...

  10. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sa...